TARA vs. FHTX, ANNX, OLMA, IMMP, NMRA, AQST, DSGN, HRTX, DMAC, and ITOS
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Foghorn Therapeutics (FHTX), Annexon (ANNX), Olema Pharmaceuticals (OLMA), Immutep (IMMP), Neumora Therapeutics (NMRA), Aquestive Therapeutics (AQST), Design Therapeutics (DSGN), Heron Therapeutics (HRTX), DiaMedica Therapeutics (DMAC), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Protara Therapeutics vs.
Foghorn Therapeutics (NASDAQ:FHTX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Protara Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Protara Therapeutics' return on equity.
Foghorn Therapeutics received 4 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Protara Therapeutics an outperform vote while only 63.49% of users gave Foghorn Therapeutics an outperform vote.
Protara Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Foghorn Therapeutics has a beta of 3.18, meaning that its stock price is 218% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
In the previous week, Foghorn Therapeutics had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.62 beat Foghorn Therapeutics' score of 0.19 indicating that Protara Therapeutics is being referred to more favorably in the news media.
Foghorn Therapeutics currently has a consensus target price of $13.17, indicating a potential upside of 198.90%. Protara Therapeutics has a consensus target price of $22.67, indicating a potential upside of 577.63%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Foghorn Therapeutics.
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Foghorn Therapeutics beats Protara Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TARA) was last updated on 3/4/2025 by MarketBeat.com Staff
Free TARA Stock Alerts